THIS IS AN AMENDMENT AGREEMENT (the "Amendment Agreement"), dated as of February 8, 2005
among West Pharmaceutical Services, Inc., a Pennsylvania corporation, ("WPS") its wholly owned subsidiary
West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., a corporation organized under the
laws of England and Wales, (together with WPS, the "West Group") and Innovative Drug Delivery Systems, Inc.,
a Delaware corporation ("IDDS").
The West Group and IDDS are parties to a License Agreement, dated as of August 25, 2000, as amended (the
"Umbrella License Agreement").
In connection with the assignment of the Umbrella License Agreement in connection with the sale of the West
Group's drug delivery business, the parties have agreed to further amend the Umbrella License Agreement.
In consideration of IDDS's consent to the assignment, and intending to be legally bound hereby, the parties agree
1. Section 6.2.2 of the Umbrella License Agreement is hereby amended to read in its entirety as follows:
"a summary balance sheet for the previous year; provided, however, that this Section 6.2.2 shall be deemed to be
satisfied so long as the information to be furnished is readily available to West or any successor or assign
(including Archimedes Pharma Limited) on the U.S. Securities and Exchange Commission's internet homepage or
at the internet homepage of IDDS or its parent within the applicable time period required under this Section 6.2."
2. Except as expressly set forth above, the Umbrella License Agreement shall continue in full force and effect
without further amendment.
3. This Amendment Agreement sets forth the entire agreement between the parties with respect to the subject
matter hereof, and supersedes all written or oral prior agreements or understanding with respect thereto. This
Amendment Agreement may be executed in counterparts and shall be governed by the laws of the
Commonwealth of Pennsylvania without regard to the conflicts of laws